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Objectives: The present study was designed to determine whether there is a relationship between indium
compound exposure and interstitial lung damage in workers employed at indium tin oxide manufacturing and
reclaiming factories in Korea.
Methods: In 2012, we conducted a study for the prevention of indium induced lung damage in Korea and
identified 78 workers who had serum indium or Krebs von den Lungen-6 (KL-6) levels that were higher than the
reference values set in Japan (3 μg/L and 500 U/mL, respectively). Thirty-four of the 78 workers underwent chest
high-resolution computed tomography (HRCT), and their data were used for statistical analysis.
Results: Geometric means (geometric standard deviations) for serum indium, KL-6, and surfactant protein D (SP-D)
were 10.9 (6.65) μg/L, 859.0 (1.85) U/mL, and 179.27 (1.81) ng/mL, respectively. HRCT showed intralobular interstitial
thickening in 9 workers. A dose–response trend was statistically significant for blood KL-6 levels. All workers who
had indium levels ≥50 μg/L had KL-6 levels that exceeded the reference values. However, dose–response trends for
blood SP-D levels, KL-6 levels, SP-D levels, and interstitial changes on the HRCT scans were not significantly
different.
Conclusions: Our findings suggest that interstitial lung changes could be present in workers with indium exposure.
Further studies are required and health risk information regarding indium exposure should be communicated to
workers and employers in industries where indium compounds are used to prevent indium induced lung damage
in Korea.
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Although pneumoconiosis is still the best-known occupa-
tional chronic lower airway disease, industrial develop-
ments in recent years have introduced new manufacturing
materials and production methods, which have been iden-
tified as new causes of occupational interstitial lung dis-
ease. Nylon flock and diacetyl used in the flavor industry
as well as indium compounds were shown to have an
association with lower airway diseases [1].
Hardly soluble indium compounds such as indium
oxide, indium zinc oxide, and indium tin oxide are used
in the manufacturing of electrically conductive film for
liquid crystal display (LCD) panels.* Correspondence: toxneuro@kosha.net
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reproduction in any medium, provided the orSince the first report of a case of indium induced
interstitial lung disease in 2003, [2] 7 other cases of in-
dium induced interstitial lung disease were identified in
Japan. In addition, 2 cases of pulmonary alveolar protei-
nosis (PAP) were reported in workers employed at an in-
dium processing facility in the United States, and 1 case
of PAP was reported in an worker exposed to indium in
China [3-5]. Interstitial and emphysematous lung damage
in workers who had been exposed to indium compounds
are called “Indium Lung” [6]. Ten cases of indium lung
disease as well as epidemiological studies suggest that
hardly soluble indium compounds cause interstitial lung
disease in workers who handle indium compounds [6-9].
Animal experiments showed that intratracheal instil-
lation or inhalation of indium compounds result in
pulmonary fibrosis [10-13]. The United States National
Toxicology Program (NTP) conducted a 2-year longd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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rats and concluded that there was clear evidence that
InP is carcinogenic [14]. In 2006, the International
Agency For Research On Cancer (IARC) classified InP
as a probable carcinogenic agent in humans (Group 2A)
[15]. Despite evidence of the harmful respiratory effects
of indium compounds, there has not yet been any stud-
ies that investigated the incidence of indium induced
interstitial lung disease in Korea. Therefore, this study
was performed to assess whether there is a relationship
between exposure to indium compounds and interstitial
lung damage in workers exposed to indium compounds
in Korea.Materials and methods
Study subjects
This study was approved by the ethics committee of Oc-
cupational Safety and Health Research Institute (OSHRI),
Korea Occupational Safety and Health Agency (KOSHA),
Incheon, Korea and conducted in accordance with the
declaration of Helsinki.
In total, 301 workers who handled indium compounds
in the course of their work, volunteered for the study for
the prevention of indium lung disease in Korea at 2012
conducted by OSHRI of KOSHA. The serum indium or
Krebs von den Lungen-6 (KL-6) concentrations of 78
workers exceeded the Japanese reference values (3 μg/L
and 500 U/mL, respectively) [16]. Among them, 34
workers (43.6%) agreed to undergo chest high-resolution
computed tomography (HRCT), and the data of these
workers were used for our statistical analysis. Health
check items included completion of the OSHRI-developed
questionnaire with past medical, job, and smoking histor-
ies as well as chest symptoms and signs, chest physical
examinations, and spirometry as well as serum indium,
KL-6, and surfactant protein D (SP-D) levels. SP-D was
not used screening health check item to determine for
Chest HRCT. Because Usefulness of SP-D in diagnosis of
indium induced interstitial lung disease was not as good
as KL-6 [6-8], and it had been listed one of secondary
health check items for prevention of indium lung disease
in Japan.
An occupational physician interviewed each of the
workers and confirmed the accuracy of the information
on the questionnaires.Spirometry
Spirometry was performed using PC-10 spirometer
(CHEST M.I., Inc., Tokyo, Japan) to get forced vital
capacity (FVC) and forced expiratory volume 1 second/
forced vital capacity (FEV1/FVC). In the sitting position,
the tests were repeated until obtaining appropriate and
reproducible results at least three times, and then thebest results were selected. All results were confirmed by
physician.
Serum KL-6 and SP-D
KL-6 is a mucin-like high molecular glycoprotein, which
is strongly expressed on alveolar type II pneumocyte
[17]. Serum KL-6 has been known one of sensitive bio-
marker for interstitial lung diseases such as idiopathic
pulmonary fibrosis, radiation pneumonitis, connective
tissue disease-associated interstitial lung disease, lung
involvement of sarcoidosis, and pulmonary alveolar pro-
teinosis [18,19].
SP-D is produced and secreted by type II pneumocyte.
It is also elevated in patient with inflammatory lung dis-
eases, including idiopathic pulmonary fibrosis and pul-
monary alveolar proteinosis [20,21].
Serum KL-6 levels were measured by enzyme-linked
immunosorbent assay (ELISA) kit (EIDIA Co., Ltd.,
Tokyo, Japan). And the concentration of serum SP-D
was measured by human surfactant protein D ELISA kit
(BioVendor, Brno, Czech). The methods and steps for
analysis of KL-6 and SP-D were followed by guidelines
presented by manufacturers. All samples for KL-6 and
SP-D were analyzed twice, and mean values were re-
ported and used for statistical analysis.
HRCT scanning and radiologic evaluation
Chest HRCT was performed at the 3 hospitals near the
factories when serum indium or KL-6 levels exceeded
the Japanese reference values. And then all HRCT films
were reviewed by a chest radiology specialist, and the re-
ports were discussed with occupational physician.
All of the subjects underwent volumetric thin section
HRCT scan. Patients were scanned caudocranially in one
breath hold; 1 mm collimation was used at a table feed
of 6 mm/0.75 s scanner rotation (8 mm/s) at 120 kV and
140 mA. Scanning was performed from the lung bases
toward the apices. The volumetric axial images with
1 mm thickness and the 1 mm intervals were recon-
structed with a high spatial frequency algorithm on supine
and prone position. The images were viewed at window
levels of −700 HU for analysis of thin section HRCT
features. All images were displayed at the lung window
setting using a PACS (picture archiving and communica-
tion system) workstation (Deja-View, Dongeun Informa-
tion technology).
The thin section HRCT scans were evaluated for the
presence and/or extent of the following features to evalu-
ate indium induced interstitial lung damage:
(1) interlobular or intralobular interstitial thickening;
(2) area of ground glass opacity (GGO); (3) area of
emphysema. These findings were defined according to
the glossary of terms recommended by the Fleischner
Society [22].




Age (yr): Mean (range) 34.7 (20–59)
Sex Male 29 (85.3)
Female 5 (14.7)
Smoking Currant smoker 15 (44.1)
Ex-smoker 16 (47.1)




Workplace ITO production 18 (52.9)
Recycling 16 (47.1)
ITO: indium tin oxide.
Table 2 The medical history of the study subjects
Past medical history N %
None 32 94.1





Diabetes mellitus 0 0
Heart disease 0 0
Total 34 100.0
Abbreviations: N number of subjects, COPD chronic obstructive
pulmonary disorder.
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and lower, right and left) by one third and two third of
the vertical distance between the lung apices and the
domes of the diaphragm. Each of these zones was evalu-
ated and scored separately for the presence and/or
extent of the features on the thin section HRCT scan.
Interlobular and intralobular interstitial thickening were
scored in each of six zones according to the subjective
score of the involved area to cross sectional area (0 = no
involvement; 1 = minimal involvement; 2 = moderate
involvement; 3 = severe involvement) as described in
other studies [23,24]. The scores of the six zones were
summated as the total scores for Interlobular and intra-
lobular interstitial thickening from 0 to 18. The remaining
features of the thin section HRCT scan (ground glass opa-
city and emphysema) were evaluated in same scoring sys-
tem for interlobular or intralobular interstitial thickening.
They were expressed as a semi-quantitative scale of grade
(score of interlobular and intralobular interstitial thicken-
ing + score of ground glass opacity + score of emphysema)
as follows: grade 0, <1; grade 1, 1–5; grade 2, 6–10; grade
3, 11–15; grade 4, >16.
Cases of grade 1 or more were regarded positive inter-
stitial changes, grade 0 or other suspected cases were
regarded negative.
Statistical analysis
We assessed whether continuous data were normally
distributed, and data sets that were not normally distrib-
uted were log-transformed before analysis. Mean values
of variables were calculated and compared with t-tests
or ANOVA, where appropriate. Prevalence data were
compared using chi-square test, Fisher’s exact tests, and
Mantel-Haenszel trend test.
To compare KL-6 and SP-D levels between groups
with low and high serum indium levels, the 34 subjects
were divided in 2 groups: subject with serum indium
levels of <10 μg/L (S-in <10) and those with ≥10 μg/L
(S-in ≥10) were grouped together. Serum indium level of
10 μg/L was simple cut-off value in considering of
number of subjects, to divide groups low and high
serum indium levels. And To analyze the dose–response
relationship between serum indium levels and KL-6
levels, SP-D levels, and HRCT finding, the workers were
classified into 6 groups according to their serum indium
levels (group 0: less than 1.0, group 1: 1.0–4.9, group 2:
5.0–9.9, group 3: 10.0–29.9, group 4: 30.0–49.9, and
group 5: ≥50.0). P values <0.05 were considered statisti-
cally significant.
Results
Characteristics of the study subjects
Table 1 shows the characteristics of the study subjects.
Eighteen of the workers were employed in the indiumtin oxide (ITO) production industry, and the remaining
16 workers were employed at recycling plants. The average
age of the 34 workers was 34.7 years (range, 20–59 years):
29 were men and 5 were women. The mean duration of
indium exposure for the group was 43.4 months. Fifteen
were current smokers, and 16 of the 19 non-current
smokers had a history of smoking. Table 2 shows the med-
ical history of our study subjects. Thirty-two of the 34
workers did not have a history of cardiopulmonary disease,
whilst 2 had a history of hypertension.
Chest symptoms and chest physical examination
The questionnaire assessed chest symptoms and in-
cluded questions regarding symptoms of cough, sputum,
chest discomfort, palpitation, and wheezing. Sixteen of
the 34 workers did not experience any of these symp-
toms, whilst 18 of the workers experienced at least 1 of
the 5 chest symptoms. The prevalence rate of respiratory
symptoms was higher amongst current smokers than
amongst non-current smokers, but statistical significance
was not reached (Table 3). The chest physical examination
results of all 34 workers were normal.






Respiratory symptoms N % N % N %
No 5 33.3 11 57.9 16 47.1 0.1542
Yes 10 66.7 8 41.1 18 52.9
34
Abbreviations: N number of subjects, P probability by Chi-square test,
Respiratory symptoms: at least one or more symptoms of cough, sputum,
chest discomfort, palpitation, and wheezing.
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Table 4 shows the results of the serum immunochemis-
try. Geometric means (GM) and geometric standard
deviations (GSD) of serum indium, KL-6, and SP-D in
the workers were 10.9 (6.7) μg/L, 859.0 (1.9) U/mL, and
179.3 (1.8) ng/mL, respectively.
The GM of KL-6 in group S-in <10 and in group
S-in ≥10 were 704.4 U/mL and 1024.6 U/mL, respectively,
and the GM of SP-D in group S-in <10 and S-in ≥10 was
135.0 ng/mL and 230.7 ng/mL, respectively. Although the
GM of KL-6 and SP-D for subjects with S-in ≥10 were
higher than that for subjects with S-in <10, only SP-D
levels differed significantly between groups, whilst differ-
ences in KL-6 levels did not reach significance.
The FEV1/FVC ratio of all 34 workers was within the
normal range of >70%, whilst the % FVC were within
the normal range of >80% for all except 2 workers.
These 2 workers had % FVC values of 73.4% and 78.8%,
respectively, and each of them had mild restrictive pat-
terns. Nine of the 34 workers had evidence of interstitial
changes on chest HRCT (Grade 1: 3 cases, Grade 2: 4
cases, Grade 3: 2 cases). The main HRCT findings were
intralobular interstitial thickening, whilst there were no
workers with ground glass opacities or emphysematous
changes.
GM and GSD of KL-6 and SP-D, prevalence (%) for
exceeding the reference values of KL-6 and SP-D, andTable 4 Serum immunochemistry
Serum immunochemistry n GM GSD Range p
Serum indium (μg/L) 34 10.9 6.7 ND-125.8
S-in <10 16 2.5 6.2 ND-9.2 <0.0001
S-in ≥10 18 39.4 2.2 11.7-125.8
KL-6 (U/mL) 34 859.0 1.9 274.6-2062.2
S-in <10 16 704.4 1.8 242.6-942.7 0.0760
S-in ≥10 18 1024.6 1.8 948.0-2062.2
SP-D (ng/mL) 34 179.3 1.8 60.0-466.1
S-in <10 16 135.0 1.7 59.9-177.0 0.0064
S-in ≥10 18 230.7 1.7 183.4-466.1
Abbreviations: GM geometric mean, GSD geometric standard deviation,
S-in serum indium, KL-6 Krebs von den Lungen-6, SP-D surfactant protein D,
P probability by Student t-test.interstitial changes on chest HRCT in each group are
shown in Table 5. Dose-dependent trends for KL-6 and
SP-D were statistically significant when age- and smoking-
adjusted multiple regression model was applied. 5.40+
0.1360* serum indium for KL-6 (p = 0.0055) and 5.25+
0.1846* serum indium for SP-D (p = 0.0005). Results of
Dunnett’s test revealed that compared to Group 0, the
means KL-6 value of groups 4 and 5 increased signifi-
cantly. Mean values of SP-D increased in patients with
serum indium levels ≥10 μg/L, but statistical significance
was not reached. The KL-6 levels of all 12 workers in
Group 4 and 5 were above the reference value. A dose–
response trend for the prevalence of SP-D, but not for the
prevalence of KL-6 and interstitial changes on HRCT, was
statistically significant. The prevalence of these changes
on the HRCT in each group was not significantly different
(0.0%–42.9%) (Figure 1).
Discussion
In this study we did not clarify the dose-effect and dose–
response relations between indium compound exposure
and interstitial lung changes on HRCT. However, we found
significant dose-effect and dose–response relations be-
tween serum indium levels and GM of KL-6 and the preva-
lence of exceeding reference value of SP-D in workers
exposed to indium, despite of the insignificant difference of
the prevalence of exceeding reference value of KL-6 and
HRCT. Although we did not include non-exposed individ-
uals in our study, our results clearly show that the GM of
KL-6 and SP-D levels were higher in workers with serum
indium levels ≥10 ug/L than in those with serum indium
levels <10 ug/L.
Our finding showed similar results the studies of Japan
[7-9] reported that workers exposed to indium com-
pounds had significantly higher serum indium, KL-6,
and SP-D levels than non-exposed workers. In addition,
serum indium level was positively correlated with KL-6
and SP-D levels. The rates of exceeding reference value
of serum indium, KL-6, and SP-D were statistically high
in exposed workers. However, the prevalence of intersti-
tial thickening on HRCT identified interstitial lung- and
emphysematous changes in exposed workers were not
significantly different from that in non-exposed workers.
These studies reported dose-effect and dose–response
relationships between serum indium and KL-6, SP-D,
and HRCT, and found no significant differences in KL-6
and SP-D levels between current smokers and non-
current smokers.
Insignificant relationship of KL-6 and HRCT in this
study might be influenced by the limited number of the
study subjects. Because relatively small number of the
workers having high level of KL-6 had volunteered for
HRCT (43.6%) when compared with that in previous
studies, the participants might be influenced by selection
Table 5 Dose–response relations between serum indium and KL-6, SP-D, and interstitial changes on chest HRCT
Serum indium (μg/L) KL-6 (U/mL) SP-D (ng/mL) Prevalence (%)
Group Range GM n GM GSD GM GSD KL-6 (>500 U/mL) SP-D (>110 ng/mL) HRCT-I
0 <1.0 0.2 3 586.1 1.3 120.9 2.9 100.0 33.3 0.0
1 1.0-4.9 3.4 7 509.6 1.7 143.8 1.5 42.9 71.4 14.3
2 5.0-9.9 7.4 6 1126.9 1.6 132.5 1.6 83.3 66.7 33.3
3 10.0-29.9 15.5 6 486.3 1.4 157.6 1.6 50.0 83.3 16.7
4 30.0-49.9 43.8 5 1539.4* 1.5 252.6 1.9 100.0 80.0 40.0
5 ≧50 81.5 7 1451.1* 1.1 299.8 1.3 100.0 100.0 42.7
p for trend 0.0055 0.0005 0.1057 0.0353 0.1198
Abbreviations: GM geometric mean, GSD geometric standard deviation, KL-6 Krebs von den Lungen-6, SP-D surfactant protein D, HRCT-I interstitial changes on
HRCT, Prevalence (%): % of workers exceeding each reference values and % of workers with interstitial changes on HRCT, p for trend: age- and smoking-adjusted
multiple regression model for GM and GSD of KL-6 and SP-D, Mantel-Haenszel trend for prevalence data, * P < 0.05 by Dunnett’s test.
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dose–response relations for all parameters of this study.
This study was conducted for screening interstitial lung
disease and gathering basic health information in indium
exposed workers, so interstitial lung damages were not
confirmed pathologically. There were no statistical dif-
ferences in the prevalence of KL-6, SP-D, and interstitial
changes as seen on HRCT between current smokers and
non-current smokers (data not shown).
The pathogenesis of indium related lung disorder is
not understood yet. According to the 2001 NTP report,
[14] the incidence of adenoma and lung cancer increased
in laboratory rats and mice exposed to InP, and the ex-
tent and severity of inflammatory lesions were muchFigure 1 High-resolution computed tomography scans on prone posi
employed at an indium tin oxide target production facility for 7 year
3 years). The image shows subpleural interlobular interstitial thickening in
respiratory diseases. Results of health examinations were as follows: serum
109.6% predicted.greater and included atypical hyperplasia, chronic inflam-
mation, alveolar epithelial hyperplasia and metaplasia, al-
veolar proteinosis, and interstitial fibrosis. In the same
manner, the reported cases related with indium found
various clinical syndromes. Interstitial thickening and em-
physematous changes in the lungs, as seen on HRCT, were
evident in 7 patients who worked in grinding process of
indium tin oxide target manufacturing factory of indium
lung disease in Japan. However, 2 patients worked in
reclaiming facility in the United States and 1 patient in
China who was exposed to indium compound in display
production.
Interstitial lung fibrosis cases in Japan showed intraal-
veolar filling of cholesterol crystal, which is pathologicaltion of a worker with no history of smoking, who had been
s (sintering room for 4 years and indium oxide powder room for
both lower lung fields (arrows). The patient had no history of
indium, 50 μg/L; KL-6, 1769 U/mL; FVC, 86% predicted; FEV1/FVC,
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ary lesion of Japanese cases were not only confined in
intraalveolar space, but also infiltrated interstitium. Thus,
Japanese cases may represent pulmonary alveolar protei-
nosis with interstitial involvement [4].
The pathogenesis of indium toxicity is not clear. There-
fore, the reasons underlying the different pathologic
findings after indium exposure remain unclear. One hy-
pothesis that could explain the pathogenesis of indium
lung disease is the notion that indium induces a “foreign
body reaction” [4,5]. This hypothesis suggests that when
indium compounds are inhaled into the lungs, a foreign
body reaction and macrophage dysfunction in the lungs
are induced, leading accumulation of intraalveolar lipo-
proteinaceous material and development of cholesterol
ester crystals with the formation of cholesterol granu-
lomas and this results in eventual interstitial fibrosis
and emphysema. However, this hypothesis does not
sufficiently explain the pathologic findings of fibrotic
foci in areas without cholesterol ester crystals. Other
undiscovered pathogenic mechanisms for indium lung
disease may exist.
Tin is a well-known cause of stannosis, benign pneumo-
coniosis without fibrosis, or necrosis [25,26]. Previous ani-
mal experiments [6-9,14] and an epidemiological study [8]
reported that tin-free indium compounds induced lung fi-
brosis. It is thought that pulmonary interstitial fibrosis in
workers exposed to indium tin oxide could be attributed
to indium compounds.
We used serum indium levels as a biological exposure
index for indium compound exposure in this study.
Based on the 2001 NTP report, [14] serum indium levels
increased proportionally with an increase in the duration
of exposure, although serum indium levels were low
relative to indium concentrations in the lungs. And the
decrease in serum indium levels was slower than indium
clearance in the lungs. KL-6 and SP-D were used as an
index to evaluate pulmonary interstitial damages. But
biological half-life of indium compound was not been
defined clearly.
Workers enrolled in our study were from different in-
dium processing facilities in different parts of Korea, and
it was therefore not possible for us to perform chest
HRCT in 1 hospital only. Therefore, the quality of chest
HRCT may not have been uniform.
Conclusion
In Korea, the demand for indium compounds increased
with the expansion of the display manufacturing indus-
try, but the extent to which indium is used in this coun-
try remains unclear. In 2011, the domestic demand for
indium in Korea was estimated to be 950 tons [27]. This
estimate was similar to the amount used in Japan in
2006 [6]. According to this estimation, Korea is one ofthe foremost consumers of indium in the world. Al-
though our study had some limitations, to our know-
ledge, it is the first investigation of indium induced
interstitial lung damage in Korea, and our results are
meaningful as an initial step in the identification and
prevention of indium induced lung damage in Korea.
Nakano et al. [7] investigated serum indium, KL-6, and
SP-D levels before and after engineering control, which
included the use of appropriate respiratory protective
devices, improvement of workplace ventilation and found
that serum indium, KL-6, and SP-D levels decreased after
these improvements. Further studies are required to clar-
ify pathogenesis of indium induced interstitial lung dam-
age. Health risk information regarding indium exposure
should be communicated to workers and employers in in-
dustries where indium compounds are used to prevent in-
dium induced lung damage in Korea.
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